Walleye Capital LLC Has $296,000 Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Walleye Capital LLC cut its holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 94.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 14,183 shares of the biopharmaceutical company's stock after selling 234,105 shares during the quarter. Walleye Capital LLC's holdings in Catalyst Pharmaceuticals were worth $296,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of the stock. Steward Partners Investment Advisory LLC acquired a new position in shares of Catalyst Pharmaceuticals in the 4th quarter valued at $27,000. Farther Finance Advisors LLC lifted its position in Catalyst Pharmaceuticals by 125.1% during the fourth quarter. Farther Finance Advisors LLC now owns 2,690 shares of the biopharmaceutical company's stock valued at $56,000 after buying an additional 1,495 shares in the last quarter. Wilmington Savings Fund Society FSB purchased a new stake in Catalyst Pharmaceuticals during the fourth quarter worth approximately $65,000. KBC Group NV increased its position in shares of Catalyst Pharmaceuticals by 48.8% in the fourth quarter. KBC Group NV now owns 4,699 shares of the biopharmaceutical company's stock worth $98,000 after acquiring an additional 1,542 shares in the last quarter. Finally, Thurston Springer Miller Herd & Titak Inc. purchased a new position in shares of Catalyst Pharmaceuticals in the 4th quarter valued at $134,000. Hedge funds and other institutional investors own 79.22% of the company's stock.

Catalyst Pharmaceuticals Price Performance

Shares of NASDAQ:CPRX traded up $0.01 on Wednesday, reaching $24.29. 942,088 shares of the company traded hands, compared to its average volume of 1,105,389. Catalyst Pharmaceuticals, Inc. has a fifty-two week low of $14.47 and a fifty-two week high of $26.16. The stock has a market capitalization of $2.96 billion, a PE ratio of 20.58, a P/E/G ratio of 3.31 and a beta of 0.79. The company's 50 day moving average is $22.70 and its 200-day moving average is $22.27.

Insider Buying and Selling at Catalyst Pharmaceuticals

In other news, insider Brian Elsbernd sold 62,975 shares of the business's stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $22.98, for a total transaction of $1,447,165.50. Following the sale, the insider now owns 188,564 shares in the company, valued at $4,333,200.72. The trade was a 25.04 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Gary Ingenito sold 44,904 shares of Catalyst Pharmaceuticals stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $22.09, for a total value of $991,929.36. Following the sale, the insider now owns 68,873 shares of the company's stock, valued at approximately $1,521,404.57. This represents a 39.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 10.40% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the company. HC Wainwright reiterated a "buy" rating and issued a $35.00 target price on shares of Catalyst Pharmaceuticals in a research note on Friday, February 28th. Robert W. Baird boosted their target price on shares of Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the stock an "outperform" rating in a research report on Monday, March 3rd. Stephens reaffirmed an "overweight" rating and set a $33.00 price target on shares of Catalyst Pharmaceuticals in a report on Thursday, February 27th. StockNews.com raised shares of Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Friday, February 28th. Finally, Bank of America reiterated a "buy" rating and set a $30.00 target price on shares of Catalyst Pharmaceuticals in a research note on Thursday, January 9th. Seven analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and an average target price of $32.29.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.